ClinicalTrials.gov
public full text
Public Domain
A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
Teva is developing laquinimod tablets as a new oral treatment for MS. Laquinimod has immunomodulating properties. In a previous clinical study laquinimod showed evidence of biological activity by reducing the number of acute brain lesions. The duration of the current study is 36 weeks.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis#1164505
- Acción de la inteligencia artificial en la rehabilitación y recuperación de la enfermedad prevalente neurológica en niños y adultos#214904
- Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma#1150767
- Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) Participants#980134
- Cortiment® MMX Pharmacokinetic Study#800521
Record · ID 876171
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive